Why Core Scientific’s latest financing and Texas build out matter for stock watchers

Core Scientific (CORZ) is in focus after its financing arm completed a US$3.3b senior secured notes offering due 2031, alongside plans to expand its Pecos, Texas campus for high density AI colocation.

At a share price of US$20.35, Core Scientific has recorded a 33.01% 1 month share price return and a 27.27% year to date share price return, while its 1 year total shareholder return of 132.84% reflects recent momentum around its financing and AI focused Texas expansion.

If you are tracking how AI infrastructure themes are playing out across the market, it can be useful to scan other names through 37 AI infrastructure stocks

With the shares up sharply over the past year and analysts’ average price target sitting around US$26.55, the key question now is whether the recent AI and financing story leaves upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 22.9% Undervalued

With Core Scientific’s fair value in the most followed narrative set at $26.40 against a last close of $20.35, the focus is on whether the AI and power build out can support that gap.

The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise. Core Scientific’s ability to diversify its customer base and reduce reliance on CoreWeave as a primary client could improve margins and provide more stable revenue streams in the long term.

Want to see what sits behind that valuation gap? The narrative leans heavily on rapid top line expansion, a sharp turn toward profitability, and a richer earnings multiple than today.

Result: Fair Value of $26.40 (UNDERVALUED)

However, there are clear pressure points, including reliance on CoreWeave for a large revenue stream and recent quarterly losses. These factors keep profitability and execution firmly in focus.

Another way to look at Core Scientific’s valuation

The narrative fair value of $26.40 suggests upside, but the current P/S ratio of 20.1x tells a more demanding story. Peers trade around 4.1x, and the fair ratio sits near 6.2x, which implies investors are paying a heavy premium. Is that premium comfort or risk for you?

To stress test that premium against the underlying numbers, it can help to see how similar companies are priced and where the market could gravitate over time. Then decide whether Core Scientific still fits your criteria through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed sentiment around Core Scientific’s valuation, growth and concentration risks makes this a good moment to review the data directly and decide where you stand, starting with the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If Core Scientific has you thinking bigger about your portfolio, do not stop here. Put the same discipline to work hunting for the next opportunity.

• Spot potential high growth names early by scanning 24 elite penny stocks with strong financials that already show stronger financial footing than many expect from lower priced shares.
• Zero in on quality at a discount by reviewing 51 high quality undervalued stocks that pair healthier balance sheets with cash flows the market may be overlooking.
• Prioritize staying power and sleep better at night by focusing on 67 resilient stocks with low risk scores that score well on stability and financial resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.